MedTrace Logo

Clotild® Smart Guidewire System (CSGS) Evaluation in EndovascUlar Thrombectomy Procedure

NCT04993079 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2026-02-27

Study results available
· View outcomes & findings →

Summary

The purpose of this First-in-Human study is to evaluate the safety of using the Clotild® system to guide the endovascular thrombectomy (EVT) device to the clot location during EVT for the treatment of an acute ischemic stroke eligible to EVT, whatever the EVT device chosen. A secondary purpose is to assess the clinical performance, defined as the feasibility of measuring clot electrophysiological parameters in vivo during EVT procedures.

Conditions

Interventions

DEVICE

Clotild® Smart Guidewire System (CSGS)

Use of Clotild® Smart Guidewire System as neurovascular guidewire

Sponsors & Collaborators

  • Sensome

    lead INDUSTRY

Principal Investigators

  • Andrew Cheung, MD · Liverpool Hospital, Liverpool NSW, Australia

  • Dennis Cordato, MD · Liverpool Hospital, Liverpool NSW, Australia

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-26
Primary Completion
2024-04-13
Completion
2024-04-16

Countries

  • Australia
  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04993079 on ClinicalTrials.gov